CarthroniX President/Chairman of the Board R. Rex Parris and Carrol Parris Donate $50,000 in Support of Life Extension Research – PRNewswire

LANCASTER, Calif., Aug. 3, 2020 /PRNewswire/ -- R. Rex Parris, President and Chairman of the Board of biotech company CarthroniX, announced a donation of $50,000 to Denis Evseenko, MD, Ph.D. of the Keck School of Medicine of USC to support continued research in the field longevity.

Dr. Evseenko was recently awarded a $1.69 million research project grant from the National Institutes of Health to address how to slow arthritis in aging joints. He has helped develop breakthroughs in molecular studies that identified and characterized the unique cell populations that form the superficial human joint cartilage zone.

Dr. Evseenko is one of the world's leading medical researchers of arthritis and how gene activity drives cartilage development. "The CDC reports that 23% of all adults, or 54 million people, have some form of arthritis and are limited in their activities due to severe joint pain," said Mr. Parris. "Dr. Evseenko's work will help tens of millions of people in this country and many more worldwide, living with arthritis's daily struggle. Now there is evidence that it will also extend the quality of life and longevity."

CarthroniX is comprised of scientists and surgeons with expertise in regenerative medicine and stem cell research. Their research is focused on creating novel small molecules to stimulate the regrowth of healthy cartilage. Dr. Evseenko's work fits seamlessly with CarthroniX's goals of extending the quality of life for millions of people. Osteoarthritis is one component of the aging process as cartilage degenerates over time, especially after injury and wear and tear.

Recently it was discovered that some of the small molecules studied to treat arthritis also reverse the aging of human cells in vitro. This gift will enable Dr. Evseenko's lab to advance to the next stage of research. The CX-1 small molecule will hopefully slow the aging of mice. If this is confirmed, CarthroniX will seek FDA approval of human trials to investigate CX-1's effect on human longevity and regeneration of vital organs. "This gift will help us explore some fundamental and transformative questions related to life span extension," said Dr. Evseenko.

CarthroniX novel technologies are proven to preserve, repair, and regenerate cartilage in joints and suppress inflammation in large animals. CarthroniX is developing two types of drugs: one that is both regenerative and anti-inflammatory, and a second that is solely anti-inflammatory.

ABOUT CarthroniX

CarthroniX is developing novel small molecules to stimulate the growth and regeneration of articular cartilage in joints. CarthroniX patented, first-in-class small molecule CX-1 activates an established regenerative pathway; they demonstrated this results in cartilage proliferation, cellular migration, and deposition of cartilaginous matrix.

Media Contact: Joe Marchelewski, [emailprotected]

SOURCE PARRIS Law Firm

Originally posted here:
CarthroniX President/Chairman of the Board R. Rex Parris and Carrol Parris Donate $50,000 in Support of Life Extension Research - PRNewswire

UPDATE – Cytovia Therapeutics Acquires Worldwide Rights to CytoImmune Therapeutics’ First-In-Class EGFR Dual-targeting CAR for NK Cell Treatment of…

August 03, 2020 15:36 ET | Source: Cytovia Therapeutics

NEW YORK and MONROVIA, Calif., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Cytovia Therapeutics, Inc (Cytovia), an emerging biopharmaceutical company developing natural killer (NK) immunotherapies for cancer, today announces that it has acquired worldwide rights from CytoImmune Therapeutics for its novel EGFR Dual-targeting CAR to be used for NK cell therapy. Cytovia will conduct and finance all future development and will apply the EGFR Dual-targeting CAR to its iPSC CAR NK technology. CytoImmune will receive an upfront equity grant in Cytovia, future development milestones, and royalties.

Dr. Daniel Teper, Chairman and CEO of Cytovia added: We are honored to collaborate with Dr. Caligiuri, a pioneer in translating biological research on NK cells into impactful therapeutics. He has published solid data with intracranial injection of EGFR CAR NK cells to support their clinical development in glioblastoma. Additionally, EGFR is a clinically validated target which will allow us to expand the use of NK cellular therapy in multiple solid tumors.

Pre-clinical proof of concept data with intracranial administration of the EGFR Dual-targeting CAR-NK cells for the treatment of glioblastoma has been published in Nature Scientific Reports. The EGFR Dual-targeting CAR targets glioblastoma cells expressing EGFR wild-type and/or the mutant EGFR vIII. A single intracranial injection of EGFR CAR NK cells reduced the growth of glioblastoma and showed a statistically significant improvement in survival in animal models. The intracranial injection of the EGFR CAR NK cells remained localized in the brain without entering the systemic circulation or infiltrating extracranial organs or tissues, thus limiting toxicity.

Michael A. Caligiuri, MD, the scientific founder of CytoImmune, has been invited and is planning to join the Cytovia Scientific Advisory Board. Dr Caligiuri is the Deana and Steve Campbell Physician in Chief Distinguished Chair and President of the City of Hope National Medical Center in Duarte, CA. Dr. Caligiuri is a world-renowned physician, scientist, builder, innovator, leader and visionary. He was elected a Member of the National Academy of Medicine for his work on NK cell biology and its clinical applications. He is a past President of the American Association for Cancer Research (AACR).

Dr Caligiuri commented: CAR NK cell therapy has the potential to transform cancer outcomes. We are excited to partner with Cytovia to rapidly bring EGFR Dual-targeting CAR NK cells, a next generation therapy, to patients with the ultimate goal of curing glioblastoma. Cytovias off-the-shelf iPSC CAR NK cell technology should increase the access to precision immunotherapy for many cancer patients.

ABOUT CAR NK CELL THERAPYChimeric Antigen Receptors (CAR) are fusion proteins that combine an extracellular antigen recognition domain with an intracellular co-stimulatory signaling domain. Natural Killer (NK) cells are modified genetically to allow insertion of a CAR. CAR NK cell therapy has demonstrated initial clinical relevance without the limitations of CAR-T, such as Cytokine Release Syndrome, neurotoxicity or Graft vs Host Disease (GVHD). Induced Pluripotent Stem Cells (iPSC) - derived CAR NKs are naturally allogeneic, available off-the-shelf and may be able to be administered on an outpatient basis. Recent developments with iPSC, an innovative technology, allow large quantities of homogeneous genetically modified CAR NK cells to be produced from a master cell bank, and thus hold promise to expand access of cell therapy for many patients.

ABOUT GLIOBLASTOMAGlioblastoma affects 290,000 new patients every year worldwide. Chemotherapy and radiotherapy lack specificity and provide limited efficacy along with high toxicity. The median overall survival from the time of diagnosis is only 14.6 months. Systemic and particularly intracranial or intratumoral immunotherapy, which can target localized and infiltrating cells, has shown initial promise in early clinical trials.

ABOUT CYTOVIA THERAPEUTICS, INC Cytovia Therapeutics Inc is an emerging biotechnology company that aims to accelerate patient access to transformational immunotherapies, addressing several of the most challenging unmet medical needs in cancer and severe acute infectious diseases. Cytovia focuses on Natural Killer (NK) cell biology and is leveraging multiple advanced patented technologies, including an induced pluripotent stem cell (iPSC) platform for CAR (Chimeric Antigen Receptors) NK cell therapy, next-generation precision gene-editing to enhance targeting of NK cells, and NK engager multi-functional antibodies. Our initial product portfolio focuses on both hematological malignancies such as multiple myeloma and solid tumors including hepatocellular carcinoma and glioblastoma. The company partners with the University of California San Francisco (UCSF), the New York Stem Cell Foundation (NYSCF) and the Hebrew University of Jerusalem. Learn more atwww.cytoviatx.com

ABOUT CYTOIMMUNE THERAPEUTICS CytoImmune Therapeutics (CytoImmune) is biotechnology company focused on the application of proprietary chimeric antigen receptors (CAR) for use in both off-the-shelf human natural killer (NK) cells and autologous cytotoxic effector T cells in the treatment of liquid and solid tumors. Our CoalesceNT platform harnesses the power of both a specific CAR and a different secretory bispecific antibody in a single construct to coordinate an immune response with CAR NK cells, cytolytic effector T cells, NK-T cells and g/d T cells. This combination of NK- and T-cell therapy expedites time-to-treatment and delivers a dynamic response that reflects both innate and adaptive immunity in an effort to reduce tumor evasion and the incidence of cancer recurrence.

Learn more at http://www.cytoimmune.com

Contact for media enquiries Sophie Badr Vice President, Corporate Affairs Sophie.badre@cytoviatx.com 1(929) 317 1565

Will Rossellini President will@cytoimmune.com 1(469) 222 2350

Read the rest here:
UPDATE - Cytovia Therapeutics Acquires Worldwide Rights to CytoImmune Therapeutics' First-In-Class EGFR Dual-targeting CAR for NK Cell Treatment of...

FDA-approved treatment puts rare cancer with skin manifestations on the map – Dermatology Times

A small group of scientists and clinicians are trying to build awareness of this cancer, and how to diagnose and treat it. While this rare and aggressive hematologic malignancy hasnt had a standardized therapeutic approach in the past, that is also changing. The FDA approved tagraxofusp (Elzonris, Stemline) in 2019 as the first medication indicated to treat BPDCN, according to a drug review published June 24, 2020 in the journal Expert Review of Anticancer Therapy.1

Progress aside, theres still a long way to go in creating awareness among dermatologists, primary care physicians, emergency department providers and pediatricians all of whom are most likely to encounter people with possible BPDCN, says Naveen Pemmaraju,M.D., associate professor in the department of leukemia at The University of Texas MD Anderson Cancer Center. Dr. Pemmaraju is senior author on the recent Expert Review of Anticancer Therapy paper, and he led the pivotal study published in April 2019 in the New England Journal of Medicine that led to the FDAs approval of tagraxofusp for the treatment of BPDCN.2

Having the clinical trial is great, but now that the drug is commercially available there was a call for what are the practical considerations for Tagraxofusp in BPDCN? Dr. Pemmaraju says. Thats why we wrote this paper.

Dermatologists, take noteDr. Pemmaraju points to three stand-out practical considerations for providers.

One is that most people in medicine have yet to even hear about the disease, he says. When people on the frontlines see skin lesions, the only way theyre going to know whether its BPDCN is with a biopsy. Tissue is the issue, as they say. If something looks irregular, abnormal and if its clinically indicated to do a biopsy, do a biopsy. A lot of these patients get mistaken for other diseases, infections, other cancers. So, I think the biopsy is important.

The need for expert review goes along with the first practical consideration.

CD123 (interleukin-3 receptor alpha unit) is overexpressed in 100% of BPDCN patients. But thats not the only way to differentiate this cancer on biopsy. CD123, CD4, CD56 as the golden triad of BPDCN, according to Dr. Pemmaraju.

Now we know there are other markers, TCL1, TCF 4, CD303 and others. When you put together these three to six markers, it helps you distinguish BPDCN, which is extraordinarily rare compared to the more common cancers like acute myeloid leukemia (AML), cutis, cutaneous t-cell lymphoma. Obviously, this differentiates completely from skin infections and all these other noncancer entities, Dr. Pemmaraju says.

The second practical consideration is that, although rare diseases commonly have limited-to-no treatment options, a therapy for BPDCN exists and more are being investigated. Studies suggest that BPDCN incidence is as low as 0.44% of all hematologic cancers and 0.7% of cutaneous lymphomas, according to the paper. Despite the low numbers, BPDCN treatment is available with tagraxofusp. Researchers are also conducting multiple clinical trials for BPDCN drugs in development, including the B-cell lymphoma-2 (BCL-2) inhibitor, venetoclax, and a chimeric antigen receptor (CAR) T-cell therapy.

The third consideration: The significance of dermatologists and dermatopathologists roles in BPDCN diagnosis.

As we educate our fellow hematologists/oncologists, we must continue to educate dermatologists, many of whom are going to see this disease for the very first time in the clinic before anybody else. I believe BPDCN will soon appear on dermatology and derm-path board exams, Dr. Pemmaraju says.

BPDCN skin lesions usually present as dark and purplish and can be maculopapular.

I would say clinically there is a somewhat distinct look, although I would add the caveat that these lesions act heterogeneously, he says.

Focusing on TagraxofuspResearchers reported that tagraxofusp, aCD123-directed cytotox, demonstrated efficacy in BPDCN patients along with an overall manageable safety profile, according to the NEJM study.

A historically deadly disease, BPDCNs median overall survival after chemotherapy had been 8 to 14 months, according to Dr. Pemmaraju. Hematopoietic stem cell transplant might prolong survival in patients healthy enough to have the stem cell transplant.

Among the 29 previously untreated patients, the survival rates of 59% at 18 months and 52% at 24 months rates that were influenced by the number of patients who went into remission after tagraxofusp therapy and could thus undergo hematopoietic stem-cell transplantation represent an improvement over rates in historically published data. We also observed a 67% overall response rate among previously treated patients. Notably, we report a meaningful survival with tagraxofusp among patients with relapsed or refractory disease (median overall survival, 8.5 months), Dr. Pemmaraju and colleagues report in the NEJM.

Interestingly, patients skin lesions went away rapidly in the vast majority of people treated with tagraxofusp, according to Dr. Pemmaraju.

Capillary leak syndrome emerged as the most drug-associated serious adverse, manifested by edema, tachycardia, hypoalbuminemia and hypotension.

There also is the issue of drug resistance. Researchers have found, in vivo, that resistance to tagraxofusp in cell lines is associated with decreased DPH1 expression and azacitadine might reverse tagraxofusp resistance.

More research is needed to study how combining tagraxofusp with other targeted therapies may improve outcomes. Research also is needed to study tagraxofusp use in pediatric patients. The FDAs approval is for tagraxofusp is as first-line therapy for BPDCN for adults and children ages 2 years and older. But only a small number of pediatric patients have been treated so far, the authors report.

DisclosureMD Anderson funded the study. Dr. Pemmaraju has received research funding/clinical trials support from Affymetrix, SagerStrong Foundation, Novaris, Stemline, Samus, AbbVie, Cellectis, Daiichi Sankyo, and Plexxikon.

References

1. Lee SS, Mccue D, Pemmaraju N. Tagraxofusp as treatment for patients with blastic plasmacytoid dendritic cell neoplasm. Expert Rev Anticancer Ther. 2020;:1-8.

2. Pemmaraju N, Lane AA, Sweet KL, et al. Tagraxofusp in Blastic Plasmacytoid Dendritic-Cell Neoplasm. N Engl J Med. 2019;380(17):1628-1637.

Read more:
FDA-approved treatment puts rare cancer with skin manifestations on the map - Dermatology Times

Stem Cell Assay Market To 2026: Growth Analysis By Manufacturers, Regions, Types And Applications – Research Newspaper

The Stem Cell Assay Market report includes overview, which interprets value chain structure, industrial environment, regional analysis, applications, market size, and forecast. This is a latest report, covering the current COVID-19 impact on the market. The pandemic of Coronavirus (COVID-19) has affected every aspect of life globally. This has brought along several changes in market conditions. The rapidly changing market scenario and initial and future assessment of the impact is covered in the report. The report provides an overall analysis of the market based on types, applications, regions, and for the forecast period from 2020 to 2026. It also offers investment opportunities and probable threats in the market based on an intelligent analysis.

This report focuses on the Global Stem Cell Assay Market trends, future forecasts, growth opportunities, key end-user industries, and market players. The objectives of the study are to present the key developments of the market across the globe.

Get a PDF Copy of the Sample Report for Free @ https://dataintelo.com/request-sample/?reportId=50697

Key List Market Participants in the Market: GE Healthcare Promega Corporation Thermo Fisher Scientific Merck KGaA Cell Biolabs Hemogenix

By Types: Viability Purification Identification

By Applications: Regenerative Medicine Clinical Research

Scope of the Stem Cell Assay Market Report:

Fill the Pre-order Inquiry Form for the Report @https://dataintelo.com/enquiry-before-buying/?reportId=50697

By Regions: North America (The USA, Canada, and Mexico) Europe (Germany, France, the UK, and Rest of Europe) Asia Pacific (China, Japan, India, and Rest of Asia Pacific) Latin America (Brazil and Rest of Latin America.) Middle East &Africa (Saudi Arabia, the UAE, South Africa, and Rest of Middle East & Africa).

Report Answers Following Questions:

To Purchase This Report, Visit https://dataintelo.com/checkout/?reportId=50697

Stem Cell Assay Market Historic Data (2015-2019):

Stem Cell Assay Market Forecast (2020-2026):

To Get this Report at an Incredible Discounts, Visit @ https://dataintelo.com/ask-for-discount/?reportId=50697

About DataIntelo: DATAINTELO has set its benchmark in the market research industry by providing syndicated and customized research report to the clients. The database of the company is updated on a daily basis to prompt the clients with the latest trends and in-depth analysis of the industry. Our pool of database contains various industry verticals that include: IT & Telecom, Food Beverage, Automotive, Healthcare, Chemicals and Energy, Consumer foods, Food and beverages, and many more. Each and every report goes through the proper research methodology, validated from the professionals and analysts to ensure the eminent quality reports.

Contact Info: Name: Alex Mathews Address: 500 East E Street, Ontario, CA 91764, United States. Phone No: USA: +1 909 545 6473 | IND: +91-7000061386 Email: [emailprotected] Website: https://dataintelo.com

View original post here:
Stem Cell Assay Market To 2026: Growth Analysis By Manufacturers, Regions, Types And Applications - Research Newspaper

More on the language of immunity – Cosmos

This continues the process from last week (the I essay) of introducing terms that will be encountered as we engage with the complexities of immunity. Ive bolded a few words and phrases that, while some may be commonplace, will be used in an unfamiliar context. Repertoire is in that category.

Repertoire is mainly owned by the entertainment and performance cultures. The repertoires of: an opera singer or solo instrumentalist; amazing strokes from a top tennis player; tricky moves by a spin bowler; and the playlist that defines the repertoires of both actors and a theatrical company like Bell Shakespeare or the fictional Good Companions in JB Priestleys novel. What were discussing here is a diversity of selected repertoires, with that selection being made first by the performers on the basis of their specific abilities and interests, then by those who care to engage by listening, buying tickets and attending an event as part of their target audience. The audience for, say, the latest Opera Australia production of Don Giovanni at Sydney Opera House will, though there may be some crossover, be largely different from that enjoying live music at a Kings Cross night club.

Immunologists use repertoire in discussing the extraordinary diversity of the adaptive immune system (See Immuno and the Red and the white essays) that has evolved to limit the damage caused by pathogens as different as measles virus and malaria. When it comes to any individual infection, what we are talking about is, in fact, three quite distinct repertoires that incorporate a diversity of highly specific recognition molecules, or receptors, expressed on three very distinct categories of immune white blood cells (WBCs) that do very different jobs in protecting us. Each cell, or lymphocyte (the terms are interchangeable here), within these populations of immune performers expresses only one highly specific receptor that, with its feet anchored firmly in the outer membrane of the cell, is made up of two protein chains. At the outer tip of these molecules, we find individually unique but enormously varied structural motifs (styles?) that bind to one or other target induced by the infectious process, in this case by SARS-CoV-2.

Taking the human performer analogy, it is these targets (we call them antigens in immunology) that are the audience selecting a high-performance repertoire from the enormous pool of possible candidates that live within each and every one of us, just as the nine billion or so human beings on our planet are the precursor pool for the top musicians and sports people selected by target audiences. Fans pay money to see them because they have great regard, or affinity for what they do. The central principle of specific immunity is that high affinity binding of an individual cell surface receptor to a particular target antigen leads to its incorporation in a selected response repertoire.

The three categories of immune lymphocytes that concern us here are the B cells, the CD4+ helper T cells and the CD8+ killer T cells. The B refers to a weird organ in birds called the Bursa of Fabricius where nave, or precursor, B cells first develop and start to express their surface receptors, the B cell receptors (BCRs). Mammals like us dont have that bursa (which has nothing to do with bursitis,) but we think that the same type of process goes on in our bone marrow (BM).

The T refers to the thymus, the organ in the neck that is large in children and gets smaller (involutes) as we age. BM stem cells travel to the thymus via the blood, where they multiply, differentiate and express the T cell receptors (TCRs) that direct the attention of the CD4+ T helpers and CD8+ T killers. After exiting the thymus into the blood, these nave T cell pools provide the narrow, antigen-selected repertoires that coalesce after infection or vaccination.

The CD of CD4 and CD8 is short for cluster of differentiation and is just part of a classification scheme for molecules on the surface of immune cells. Currently, there are 371 members in this molecular club some of which are differentially expressed on the surface of antigen-selected immune T cells (and B cells) as they multiply, then go down different functional pathways. These CD activation markers allow us to characterise distinct CD4+ and CD8+ T cell subsets.

The BCRs on naive B cells are an early form of the immunoglobulin (Ig), or antibody molecules that we met last week. By the time the Igs are being secreted by the B cell descendants, the large protein factory plasma cells, the BCRs will have been refined and changed by a process called affinity maturation that is unique for the B cell/plasma cell lineage and does not happen for the T cells. More of that later.

The CD4+ T helpers are, if you use the performer analogy, the agents and promotors of immunity. The CD8+ T killers are the assassins, the killers within that sounds a bit dangerous, but they are very important. Enough for now!

This article is the latest in theSetting it Straightseries written by Laureate ProfessorPeter Dohertyfrom Australias University of Melbourne and Doherty Institute to explain aspects of the evolving COVID-19 pandemic. You can read them allhere.

See the article here:
More on the language of immunity - Cosmos

Regenerative Medicine Products to Discern Magnified Growth During 2019-2025 – Owned

Analysis of the Global Regenerative Medicine Products Market

The presented global Regenerative Medicine Products market report provides reliable and credible insights related to the various segments and sub-segments of the market. The market study throws light on the various factors that are projected to impact the overall dynamics of the global Regenerative Medicine Products market over the forecast period (20XX-20XX).

According to the report, the value of the Regenerative Medicine Products market was estimated to reach ~US$ XX in 2019 and attain a market value of ~US$ XX by the end of 2029. Further, the study reveals that the market is set to grow at a CAGR of XX% during the forecast period owing to a plethora of factors.

Get PDF Sample Copy of this Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) @ https://www.marketresearchhub.com/enquiry.php?type=S&repid=2630513&source=atm

The market study aims to provide answers to the following questions related to the Regenerative Medicine Products market:

The report splits the global Regenerative Medicine Products market into different market segments such as:

The region-wise segmentation offers critical information such as the market share, size, revenue analysis, growth prospects, and market attractiveness of each region.

Do You Have Any Query Or Specific Requirement? Ask to Our Industry [emailprotected] https://www.marketresearchhub.com/enquiry.php?type=E&repid=2630513&source=atm

Market Segment Analysis The research report includes specific segments by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2015 to 2026. Understanding the segments helps in identifying the importance of different factors that aid the market growth. Segment by Type, the Regenerative Medicine Products market is segmented into Cell Therapy Tissue Engineering Biomaterial Others

Segment by Application Dermatology Cardiovascular CNS Orthopedic Others

Global Regenerative Medicine Products Market: Regional Analysis The Regenerative Medicine Products market is analysed and market size information is provided by regions (countries). The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type and by Application segment in terms of sales and revenue for the period 2015-2026. The key regions covered in the Regenerative Medicine Products market report are: North America U.S. Canada Europe Germany France U.K. Italy Russia Asia-Pacific China Japan South Korea India Australia Taiwan Indonesia Thailand Malaysia Philippines Vietnam Latin America Mexico Brazil Argentina Middle East & Africa Turkey Saudi Arabia U.A.E Global Regenerative Medicine Products Market: Competitive Analysis This section of the report identifies various key manufacturers of the market. It helps the reader understand the strategies and collaborations that players are focusing on combat competition in the market. The comprehensive report provides a significant microscopic look at the market. The reader can identify the footprints of the manufacturers by knowing about the global revenue of manufacturers, the global price of manufacturers, and sales by manufacturers during the forecast period of 2015 to 2019. The major players in global Regenerative Medicine Products market include: Acelity DePuy Synthes Medtronic ZimmerBiomet Stryker MiMedx Group Organogenesis UniQure Cellular Dynamics International Osiris Therapeutics Vcanbio Gamida Cell Golden Meditech Cytori Therapeutics Celgene Vericel Corporation Guanhao Biotech Mesoblast Stemcell Technologes Bellicum Pharmaceuticals

Vital data enclosed in the report:

You can Buy This Report from Here @ https://www.marketresearchhub.com/checkout?rep_id=2630513&licType=S&source=atm

Read the rest here:
Regenerative Medicine Products to Discern Magnified Growth During 2019-2025 - Owned

Cryopreservation Media Market Highly Favourable with new Demand to the Growth Rate by 2025 – Market Research Posts

AMA Research added a comprehensive research document of 200+ pages on Cryopreservation Media market with detailed insights on growth factors and strategies. The study segments key regions that includes North America, Europe, Asia-Pacific with country level break-up and provide volume* and value related cross segmented information by each country. Some of the important players from a wide list of coverage used under bottom-up approach are Thermo Fisher Scientific, Inc. (United States), Osiris Therapeutics, Inc (United States), Sigma-Aldrich Corporation (United States), VWR Corporation (United States), Biolife Solutions, Inc. (United States), Lifeline Scientific, Inc. (United States), Cesca Therapeutics, Inc. (United States), BioCision, LLC (United States), Core Dynamics, Ltd. (Israel), Custom Biogenic Systems, Inc. (United States), So-Low Environmental Equipment Co., Inc. (United States), Princeton Cryotech, Inc. (United States).

Request a sample report @ https://www.advancemarketanalytics.com/sample-report/16856-global-cryopreservation-media-market

Cryopreservation Media is designed to maintain and preserve cells at low environmental temperature and decreases the risk of infection by microbes and other cell types. It provides a safe environment for cells and tissues while undergoing freezing, storage and thawing process. This is specially framed media which contains a defined serum substitute as well as an improved concentration of a cryopreservative that increases the recovery and viability of healthy cells compared to conventional freezing media.

Market Segmentation & Scope

Study by Type (Lysogenic broth, Protein-free media, Specialty media, Serum-free media, Chemically-defined media), Application (Biobanks, Gene Banks, Hospitals, Tissue engineering, Stem cell technologies, Therapeutic Applications, Cancer and Research Applications, Clinical Trials, Others), Bio-specimens Types (Human Tissue Samples, Stem Cells, Organs, Others)

Global Cryopreservation Media Market Report offers a detailed overview of this market and discusses the dominant factors affecting the growth of the market. The impact of Porters five armies on the market over the next few years has been discussed for a long time in this study. We will also forecast global market size and market outlook over the next few years.

Types of Products, Applications and Global Cryopreservation Media Market Report Geographical Scope taken as the Main Parameter for Market Analysis. This Research Report Conducts an assessment of the industry chain supporting this market. It also provides accurate information on various aspects of this market, such as production capacity, available production capacity utilization, industrial policies affecting the manufacturing chain and market growth.

Avail 30-50% Discount on various license type on immediate purchase @ https://www.advancemarketanalytics.com/request-discount/16856-global-cryopreservation-media-market

A View on Influencing Trends:

Adoption in Conserving Cord Blood Stem Cells of Newborns

The increasing Trend of Cryopreservation of Eggs and Embryos

Growth Drivers in LimelightIncreasing Healthcare Expenditure

Increasing R&D Investments

Advancement in Biobanking

Advances in Regenerative Medicine

Challenges that Market May Face:Lack of Consumer Awareness Regarding Cryopreservation Media

The report concludes with in-depth details on the business operations and financial structure of leading vendors in the Global Cryopreservation Media market report, Overview of Key trends in the past and present are in reports that are reported to be beneficial for companies looking for venture businesses in this market. Information about the various marketing channels and well-known distributors in this market was also provided here. This study serves as a rich guide for established players and new players in this market.

Check Complete Table of Content @ Table of Content @ https://www.advancemarketanalytics.com/reports/16856-global-cryopreservation-media-market

Country level Break-up includes:

North America (United States, Canada and Mexico)

Europe (Germany, France, United Kingdom, Spain, Italy, Netherlands, Switzerland, Nordic, Others)

Asia-Pacific (Japan, China, Australia, India, Taiwan, South Korea, Middle East & Africa, Others)

Extracts from Table of Contents

Global Cryopreservation Media Market Research Report

Chapter 1 Global Cryopreservation Media Market Overview

Chapter 2 Global Economic Impact on Industry

Chapter 3 Global Market Competition by Manufacturers

Chapter 4 Global Revenue (Value, Volume*) by Region

Chapter 5 Global Supplies (Production), Consumption, Export, Import by Regions

Chapter 6 Global Revenue (Value, Volume*), Price* Trend by Type

Chapter 7 Global Market Analysis by Application

.continued

This report also analyzes the regulatory framework of the Global Markets Cryopreservation Media Market Report to inform stakeholders about the various norms, regulations, this can have an impact. It also collects in-depth information from the detailed primary and secondary research techniques analyzed using the most efficient analysis tools. Based on the statistics gained from this systematic study, market research provides estimates for market participants and readers.

Key Development Activities:

On March 30, 2017, Osiris Therapeutics, Inc. (Pink Sheets: OSIR), a leading regenerative medicine company focused on developing and marketing products for wound care, orthopedics, and sports medicine, announced today that it has developed cutting edge technology enabling the preservation of living cells and tissues at ambient temperatures. Osiris has developed Prestige Lyotechnology. Unlike all other known lyophilization methods, Prestige Lyotechnology enables the preservation of living cells within tissues while stored at ambient temperatures. This novel technology developed by Osiris will benefit the entire field of cellular therapies. It is expected to accelerate development, commercialization and widespread use of living cell and tissue therapies.

Buy full version of this report @ https://www.advancemarketanalytics.com/buy-now?format=1&report=16856

About Author:

Advance Market Analytics is Global leaders of Market Research Industry provides the quantified B2B research to Fortune 500 companies on high growth emerging opportunities which will impact more than 80% of worldwide companies revenues.

Our Analyst is tracking high growth study with detailed statistical and in-depth analysis of market trends & dynamics that provide a complete overview of the industry. We follow an extensive research methodology coupled with critical insights related industry factors and market forces to generate the best value for our clients. We Provides reliable primary and secondary data sources, our analysts and consultants derive informative and usable data suited for our clients business needs. The research study enable clients to meet varied market objectives a from global footprint expansion to supply chain optimization and from competitor profiling to M&As.

Contact Us:

CRAIG FRANCIS (PR & Marketing Manager)

[emailprotected]

Ph: +1 (206) 317 1218

Read more:
Cryopreservation Media Market Highly Favourable with new Demand to the Growth Rate by 2025 - Market Research Posts

Cell and Gene Therapy Market Size to Reach over $14 Billion by 2025 – Arizton – PRNewswire

CHICAGO, July 30, 2020 /PRNewswire/ -- The global cell and gene therapy market is expected to grow at a CAGR of over 30% during the period 20192025.

Key Highlights Offered in the Report:

Key Offerings:

Get your sample today! https://www.arizton.com/market-reports/cell-and-gene-therapy-market

Cell and Gene Therapy Market Segmentation

Cell and Gene Therapy Market by Product

Cell and Gene Therapy Market by Disease

Cell and Gene Therapy Market by End-user

Cell and Gene Therapy Market Dynamics

Cell & gene therapies are emerging as the most dynamic field in medicine with a lot of ongoing R&D. Various components under cell & gene therapy such as injectable-based cell therapy, tissue-based products, vector-based gene therapy, and cell-based immunotherapy are witnessing cutting edge research to advance the clinical indications for these products. Vendors are actively conducting clinical trials to gain regulatory approval in different countries and regions with huge untapped potential.

Key Drivers and Trends fueling Market Growth:

Cell and Gene Therapy Market Geography

North America dominated the market and plays an important role in the adoption of cell & gene therapies. However, the initial product development and approvals started in China, Japan, and Europe. Post the approval of medicines in the US in 2017, the market in North America witnessed faster growth, and funds across the globe started flowing into clinical trials in the region. Many vendors started acquiring smaller companies to enter the North American region.

Get your sample today! https://www.arizton.com/market-reports/cell-and-gene-therapy-market

Cell and Gene Therapy Market by Geography

Prominent Vendors

Other Prominent Vendors

Explore our healthcare & lifesciences profileto know more about the industry.

Read some of the top-selling reports:

About Arizton:

AriztonAdvisory and Intelligence is an innovation and quality-driven firm, which offers cutting-edge research solutions to clients across the world. We excel in providing comprehensive market intelligence reports and advisory and consulting services.

We offer comprehensive market research reports on industries such as consumer goods & retail technology, automotive and mobility, smart tech, healthcare, and life sciences, industrial machinery, chemicals and materials, IT and media, logistics and packaging. These reports contain detailed industry analysis, market size, share, growth drivers, and trend forecasts.

Arizton comprises a team of exuberant and well-experienced analysts who have mastered in generating incisive reports. Our specialist analysts possess exemplary skills in market research. We train our team in advanced research practices, techniques, and ethics to outperform in fabricating impregnable research reports.

Mail:[emailprotected] Call:+1-312-235-2040 +1-302-469-0707

SOURCE Arizton Advisory & Intelligence

Here is the original post:
Cell and Gene Therapy Market Size to Reach over $14 Billion by 2025 - Arizton - PRNewswire

Meso Numismatics Update on 2nd Transaction with Global Stem Cells – GlobeNewswire

July 31, 2020 15:58 ET | Source: Meso Numismatics, Inc.

LAS VEGAS, NV, July 31, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE Meso Numismatics, Inc. (Meso Numismatics or the Company) (MSSV), a technology and numismatic company specializing in the Meso Region, including Central America and the Caribbean, announced today that the Company has recently successfully made the second payment ($75,000) to Global Stem Cells Group on time as per the companys LOI amendment dated April 22, 2020.

We are excited about the pending acquisition of Global Stem Cells Group, said David Christensen, CEO and President of Meso Numismatics, Inc. We are extremely optimistic about the opportunities that Stem Cell Biotechnology and the future that Regenerative Medicine can offer the world.

This press release should be read in conjunction with the all other filings on http://www.sec.gov

For more information on Global Stem Cells Group please visit: http://www.stemcellsgroup.com

About Meso Numismatics: Meso Numismatics, Corp is an emerging numismatic and technology company specialized in the Meso Region, including Central America and the Caribbean. The Company has quickly become the central hub for rare, exquisite, and valuable inventory for not only the Meso region, but for exceptional items from around the world. With the Company's breadth of business experience and technology team, the Company will continue to help companies grow.

Forward-Looking Statements

Some information in this document constitutes forward-looking statements or statements which may be deemed or construed to be forward-looking statements, such as the closing of the share exchange agreement. The words plan, "forecast", "anticipates", "estimate", "project", "intend", "expect", "should", "believe", and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve, and are subject to known and unknown risks, uncertainties and other factors which could cause the Company's actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. The risks, uncertainties and other factors are more fully discussed in the Company's filings with the U.S. Securities and Exchange Commission. All forward-looking statements attributable to Lans Holdings Inc., herein are expressly qualified in their entirety by the above-mentioned cautionary statement. Lans Holdings Inc. disclaims any obligation to update forward-looking statements contained in this estimate, except as may be required by law.

For further information, please contact: Investor.relations@mssvinc.com Telephone: (800) 956-3935

Read the original:
Meso Numismatics Update on 2nd Transaction with Global Stem Cells - GlobeNewswire

Regenerative Medicine Market 2020 | Research Objectives and Methodology, Growth Analysis, Top Manufacturers Sales, and Cost Structures Forecast 2024 -…

Becton Dickinson and Company

Report Highlights:

For More Information or Query or Customization Before Buying, Visit at https://www.industryresearch.co/enquiry/pre-order-enquiry/14244620

Key Market Trends:

Dermatology is the Segment by Application that is Expected to be the Largest During the Forecast Period

Dermatology is estimated to have the largest share in revenue generation, and this high contribution is attributive to the presence of easy grafting techniques for dermatological wounds and diseases. Skin, being an organ with great cell replication characteristics, provides various types of stem cells from its different layers. Therefore, there are a broad range of products present, from patches to cure small injuries to matrix and grafts for chronic wounds and burns. Thus, the segment is expected to continue to dominate the market through to the forecast period.

The increasing number of accidents and bone defects is also expected to drive the regenerative medicine market. There are also several research studies that are being conducted on tissue engineering for the development of bone graft substitutes, with the help of regenerative medicine. So, with the new advances in bone graft, the market is expected to grow over the forecast period.

North America Holds the Largest Share and is Expected to Follow the Same Trend Over the Forecast Period

North America is estimated to have the largest share, in terms of revenue, owing to the presence of major players and rapid advances in technology, along with high investments in stem cell and oncology research. There is also an increasing prevalence of diseases, such as cancer and diabetes, which can now be cured by various stem cell therapies. Additionally, the awareness regarding the available stem cell procedures and therapies among people is rising, which in turn, is increasing the demand for the overall market.

The Report Covers:

Purchase this Report (Price 4250 USD for single user license) https://www.industryresearch.co/purchase/14244620

Detailed TOC of Regenerative Medicine Market Report 2020-2024:

1 INTRODUCTION 1.1 Study Deliverables 1.2 Study Assumptions 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS 4.1 Market Overview 4.2 Market Drivers 4.2.1 Increasing Adoption of Stem Cell Technology 4.2.2 Technological Advancements in Regenerative Medicine 4.3 Market Restraints 4.3.1 Regulatory and Ethical Issues 4.3.2 High Cost of Treatments 4.4 Porters Five Forces Analysis 4.4.1 Threat of New Entrants 4.4.2 Bargaining Power of Buyers/Consumers 4.4.3 Bargaining Power of Suppliers 4.4.4 Threat of Substitute Products 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION 5.1 By Type of Technology 5.1.1 Stem Cell Therapy 5.1.2 Biomaterial 5.1.3 Tissue Engineering 5.1.4 Other Types of Technologies 5.2 By Application 5.2.1 Bone Graft Substitutes 5.2.2 Osteoarticular Diseases 5.2.3 Dermatology 5.2.4 Cardiovascular 5.2.5 Central Nervous System 5.2.6 Other Applications 5.3 Geography 5.3.1 North America 5.3.1.1 United States 5.3.1.2 Canada 5.3.1.3 Mexico 5.3.2 Europe 5.3.2.1 Germany 5.3.2.2 United Kingdom 5.3.2.3 France 5.3.2.4 Italy 5.3.2.5 Spain 5.3.2.6 Rest of Europe 5.3.3 Asia-Pacific 5.3.3.1 China 5.3.3.2 Japan 5.3.3.3 India 5.3.3.4 Australia 5.3.3.5 South Korea 5.3.3.6 Rest of Asia-Pacific 5.3.4 Middle East & Africa 5.3.4.1 GCC 5.3.4.2 South Africa 5.3.4.3 Rest of Middle East & Africa 5.3.5 South America 5.3.5.1 Brazil 5.3.5.2 Argentina 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE 6.1 Company Profiles 6.1.1 Allergan 6.1.2 Osiris Therapeutics 6.1.3 Integra Lifesciences 6.1.4 Cook Biotech Incorporated 6.1.5 Organogenesis Inc. 6.1.6 Baxter 6.1.7 Medtronic 6.1.8 Thermo Fisher Scientific 6.1.9 Sigma-Aldrich Co. 6.1.10 Becton Dickinson and Company

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

Contact Us:

Name: Ajay More

Phone: US +14242530807/ UK +44 20 3239 8187

Email: [emailprotected]

Our Other Reports:

Oral Cholera Vaccine Market Share 2020 Competitive Landscape, Industry Size, Future Trends, Top Manufacturers and Growth Factors till 2024

Hemodialysis Equipment Market Growth Rate by Share 2020-2025 | Revenue Forecast by Product Type, Applications and Regions and COVID-19 impact on Global Industry

Compression Therapy Market Size 2020-2026 Production, Sales and Consumption Status and Prospects Professional Market Research, COVID-19 Analycis

Ligating Clips Market Share, Top Manufacturers 2020 Future Growth Rate, Industry Size, Business Strategy, Demand Status by 2026 Research Includes COVID-19 Analysis

Handheld GPS Market Global Growth Rate Forecast by Regions 2020 | Future Trends with Key Manufacturers, Development Status till 2024 Industry Research.co

Trial Size Supplements Market 2020 Global Industry Revenue, Key Strategies, Business Growth Rate by Size, and Top Key Players with COVID-19 Outbreak Forecast to 2025

See more here:
Regenerative Medicine Market 2020 | Research Objectives and Methodology, Growth Analysis, Top Manufacturers Sales, and Cost Structures Forecast 2024 -...